MedAvail (MDVLQ) 10-Q 8 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 07, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS RENS TECHNOLOGY INC.
Entity Central Index Key	0001402479
Trading Symbol	MYOS
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		9,170,658

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 2,197	$ 15
Accounts receivable, net	19	78
Other current asset		1,124
Inventories, net	1,686	1,676
Prepaid expenses	153	10
Total current assets	4,055	2,903
Other asset	50	50
Deferred offering costs	92	108
Operating lease right of use asset	224
Fixed assets, net	142	149
Intangible assets, net	1,173	1,245
Total assets	5,736	4,455
Current liabilities:
Accounts payable	211	236
Accrued expenses and other current liabilities	118	383
Operating lease liabilities - current portion	46
Related party promissory note payable and accrued interest	775	1,015
Total current liabilities	1,150	1,634
Long-term liabilities:
Operating lease liabilities - net of current portion	185
Total liabilities	1,335	1,634
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 12,000,000 shares authorized at March 31, 2019 and December 31, 2018; 9,170,658 and 7,481,723 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	9	8
Additional paid-in capital	40,434	37,880
Accumulated deficit	(36,042)	(35,067)
Total stockholders' equity	4,401	2,821
Total liabilities and stockholders' equity	$ 5,736	$ 4,455

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	12,000,000	12,000,000
Common stock, shares issued	9,170,658	7,481,723
Common stock, shares outstanding	9,170,658	7,481,723

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net revenues	$ 149	$ 57
Cost of sales	61	31
Gross profit	88	26
Operating expenses:
Selling, marketing and research	275	394
Personnel and benefits	420	417
General and administrative	356	427
Total operating expenses	1,051	1,238
Operating loss	(963)	(1,212)
Other (expense) income, net	(12)	(1)
Net loss	$ (975)	$ (1,213)
Net loss per share attributable to common shareholders:
Basic and diluted	$ (0.13)	$ (0.19)
Weighted average number of common shares outstanding:
Basic and diluted	7,669,181	6,504,590

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities:
Net loss	$ (975)	$ (1,213)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation	7	11
Amortization	72	72
Stock-based compensation	243	123
Changes in operating assets and liabilities:
Decrease in accounts receivable	59	3
Increase in inventories	(10)	(3)
Increase in operating lease right of use asset	224
Decrease (increase) in prepaid expenses and other assets	995	2
Increase in operating lease liabilities	(231)
Increase (decrease) in accounts payable and accrued expenses	(280)	16
Net cash provided by (used in) operating activities	104	(989)
Cash Flows From Financing Activities:
Proceeds from registered direct offering of common stock, net	228	296
Net proceeds from issuance of common stock in private placement	1,850
Net cash provided by financing activities	2,078	296
Net increase (decrease) in cash	2,182	(693)
Cash at beginning of period	15
Cash at end of period	2,197	230
Supplemental schedule of non-cash investing and financing activities:
Conversion of related party promissory note payable into shares of common stock	250
Reclassification of deferred offering costs to additional paid in capital	$ 16	$ 6

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Beginning balance at Dec. 31, 2017	$ 6	$ 36,202	$ (31,844)	$ 4,364
Beginning balance, shares at Dec. 31, 2017	6,340,604
Net proceeds from sale of common stock	$ 1	289		290
Net proceeds from sale of common stock, shares	140,295
Stock-based compensation expense		123		123
Stock-based compensation expense, shares	55,147
Net loss			(1,213)	(1,213)
Ending balance at Mar. 31, 2018	$ 7	36,614	(33,057)	3,564
Ending balance, shares at Mar. 31, 2018	6,536,046
Beginning balance at Dec. 31, 2018	$ 8	37,880	(35,067)	2,821
Beginning balance, shares at Dec. 31, 2018	7,481,723
Net proceeds from sale of common stock		212		212
Net proceeds from sale of common stock, shares	111,129
Net proceeds from private placement of stock	$ 1	1,849		1,850
Net proceeds from private placement of stock, shares	1,267,123
Issuance of common stock upon conversion of related party promissory note payable		250		250
Issuance of common stock upon conversion of related party promissory note payable, shares	171,233
Stock-based compensation expense		42		42
Issuance of restricted stock		201		201
Issuance of restricted stock, shares	139,450
Net loss			(975)	(975)
Ending balance at Mar. 31, 2019	$ 9	$ 40,434	$ (36,042)	$ 4,401
Ending balance, shares at Mar. 31, 2019	9,170,658

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Liquidity	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY Basis of Presentation The accompanying condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial statements as of March 31, 2019 have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 27, 2019. The unaudited interim condensed consolidated financial statements presented herein reflect all normal adjustments that are, in the opinion of management, necessary for a fair presentation of the statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim condensed consolidated financial statements included in this report. The results of any interim period are not necessarily indicative of the results for the full year. Nature of Operations MYOS RENS Technology Inc. is an emerging company focused on the discovery, development and commercialization of products that improve muscle health and performance. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. On March 17, 2016, the Company merged with its wholly-owned subsidiary and changed its name from MYOS Corporation to MYOS RENS Technology Inc. As used in these financial statements, the terms “the Company”, “MYOS”, “our”, or “we”, refers to MYOS RENS Technology Inc. and its subsidiary, unless the context indicates otherwise. We continue to pursue additional distribution and branded sales opportunities. There can be no assurance that we will be able to secure distribution arrangements on terms acceptable to us, or that we will be able to generate significant sales of our current and future branded products. We expect to continue developing our own core branded products in markets such as functional foods, sports and fitness nutrition and to pursue international sales opportunities. We remain committed to continuing our focus on various clinical trials in support of enhancing our commercial strategy as well as enhancing our intellectual property assets, to develop product improvements and new products, and to reduce the cost of our products by finding more efficient manufacturing processes and contract manufacturers. Strategic Investment Transaction On December 17, 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RENS Technology Inc. (the “Purchaser”), pursuant to which the Purchaser agreed to invest $20.25 million in the Company in three tranches (the “Financing”) in exchange for an aggregate of 3,537,037 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”). In the first tranche, which closed on March 3, 2016, the Purchaser acquired 1,500,000 Shares and a warrant to purchase 375,000 shares of Common Stock (the “Initial Warrant”) for $5.25 million. On August 19, 2016, the Purchaser notified the Company that it did not intend to fulfill its obligation to fund the second tranche of the Financing in accordance with terms of the Purchase Agreement. On January 6, 2017, the Company commenced an action in the Supreme Court of New York, County of New York (the “Court”), against the Purchaser, RENS Agriculture, the parent company of the Purchaser, and Ren Ren, a principal in both entities and one of our directors, arising from the Purchaser’s breach of the Purchase Agreement. See NOTE 15-LEGAL PROCEEDINGS. Going Concern and Liquidity The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, which contemplates the continuation of the Company as a going concern. The Company has suffered recurring losses from operations and incurred a net loss of approximately $975 for the three months ended March 31, 2019 and $3,223 for the year ended December 31, 2018. As of March 31, 2019 the Company had cash of $2,197 and working capital of $2,905 (current assets of $4,055 less current liabilities of $1,150). For the three months ended March 31, 2019 and 2018, our net loss was $975 and $1,213 respectively. For the three months ended March 31, 2019 net cash provided by operating activities was $104. For the three months ended March 31, 2018 net cash used in operating activities was $989. The Company has historically recorded minimal sales during the past nineteen consecutive quarters. In June 2018, the Company launched a Fortetropin ® TM ® As of the filing date of this Form 10-Q, management believes that there may not be sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. Accordingly, the Company is evaluating various alternatives, including reducing operating expenses, securing additional financing through debt or equity securities to fund future business activities and other strategic alternatives. There can be no assurance that the Company will be able to generate the level of operating revenues in its business plan, or if additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects may be adversely affected. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. At-the-Market Offering On February 21, 2017, the Company entered into a sales agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) which established an at-the-market equity program pursuant to which the Company may offer and sell up to $6.0 million of its shares of common stock from time to time through H.C. Wainwright. The Company incurred $125 of deferred offering costs in connection with this program which were originally recorded as a long term other asset on the Company’s condensed consolidated balance sheets. Since this sales agreement expired by June 30, 2018 the remaining deferred offering costs of $96 were recognized as legal expenses recorded within the accompanying condensed consolidated statements of operations as general and administrative expenses in the three months ended March 31, 2018. On January 19, 2018, the Company sold 140,295 shares of common stock for $2.111 per share for gross proceeds of $296 in an at-the-market offering. On various dates in April 2018, the Company sold an aggregate of 131,225 shares of common stock at various prices for aggregate gross proceeds of $176 under the Company’s existing at-the-market program. A total of 771,520 shares were sold under this program for aggregate gross proceeds of $1,544. On July 24, 2018, the Company entered into a new sales agreement with H.C. Wainwright which established a new at-the-market equity program pursuant to which the Company may offer and sell shares of common stock from time to time through H.C. Wainwright. The Company incurred $108 of deferred offering costs in connection with the execution of this new sales agreement which was recorded as a long term other asset on the Company’s condensed consolidated balance sheets as of December 31, 2018. The deferred offering costs will be reflected as a reduction in equity as the Company incurs sales of its stock pursuant to this program. For the three months ended March 31, 2019, $16 was recognized and reclassified to additional paid in capital. Management continues to evaluate the ongoing progress of this program and its related outstanding deferred offering costs. On January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019, the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $146 in an at-the-market offering. As of the filing date of this Form 10-Q, a total of 882,649 shares were sold under this program for aggregate gross proceeds of $1,755. Private Placement On April 25, 2018, the Company entered into a securities purchase agreement with private investors providing for the issuance and sale by the Company of 806,452 shares of common stock, in a private placement offering at a purchase price of $1.24 per share, for gross proceeds of $1,000 and net proceeds of $978. On March 27, 2019, the Company entered into a securities purchase agreement with private investors providing for the issuance and sale by the Company of 1,438,356 shares of common stock, in a private placement offering at a purchase price of $1.46 per share, for gross proceeds of $1,850 and $250 related to the conversion of a related party promissory note payable. Promissory Note Payable On August 30, 2018, the Company executed an unsecured promissory note (the “Note”) in the principal amount of up to $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). Pursuant to the Note, on August 30, 2018, the Lender advanced $500 of funds to the Company. On September 27, 2018, the Lender advanced an additional $250 of funds to the Company. On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. The Company drew down an additional $250 under the Note in December 2018. On March 27, 2019 $250 of the Note was converted into 171,233 shares in connection with a private placement transaction. The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The proceeds of the Note will be used by the Company for general working capital purposes. As of March 31, 2019, the Company accrued $25 of interest expense on the Note.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The accompanying condensed c onsolidated financial statements include the accounts of MYOS RENS Technology Inc. and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated in consolidation. Reclassification of Prior Period Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no impact on the Company’s prior year net loss or stockholders’ equity. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statement s and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated f inancial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the amount of deferred offering costs recognized, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts. Management believes that we have the ability to sell raw materials to a third party in the event the Company does not obtain the requisite amount of revenue. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2019 and December 31, 2018 the Company had no cash equivalents. As part of our ongoing liquidity assessments, management evaluates our cash and cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The amount of funds held in these accounts can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits. Inventory Reserves Inventories are valued at the lower of cost or net realizable value, with cost determined on a first in, first-out basis. Each quarter the Company evaluates the need for a change in the inventory reserve based on projected future sales and expiration dates of products. Our policy is to recognize an inventory reserve as a loss in earnings in the period in which evidence exists that the net realizable value of inventory is less than its cost due to damage, physical deterioration, obsolescence, and changes in inventory reserve estimates, changes in price levels or other causes. Net realizable value is the estimated selling price in the ordinary course of business, less costs to complete and sell finished goods, including direct selling costs such as transportation and sales commissions as well as inventory write-offs. The multiple possible outcomes that can result from applying lower of cost or net realizable value can make inventory valuation highly complex. For the three months ended March 31, 2019 no additional reserve was recorded within cost of sales on the condensed consolidated statements of operations. Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations during the period in accordance with SEC guidance. Since the February 21, 2017 sales agreement expired by June 30, 2018 the remaining deferred offering costs of $96 on the Company’s condensed consolidated balance sheets were recognized and recorded within the Company’s condensed consolidated statements of operations as general and administrative expenses. On July 24, 2018, the Company entered into a new sales agreement, incurring $108 of deferred offering costs. As of March 31, 2019, $92 of deferred offering costs is included as a long term asset on the accompanying condensed consolidated balance sheet. Leases The Company determines if an arrangement is a lease at inception. Operating lease assets and liabilities are included in operating lease right of use (“ROU”) lease assets, current portion of operating lease liabilities, and long term operating lease liabilities on the Company’s condensed consolidated balance sheets. Operating lease right of use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right of use assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Since the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating right of use assets also include any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Fair Value of Long-Lived Assets We test long-lived assets, including fixed assets and intangibles with finite lives, for recoverability when events or changes in circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate we utilize to evaluate potential investments. We estimate fair value based on the information available in making the necessary estimates, judgments and projections. Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset’s useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the condensed consolidated statements of operations. Depreciation is provided using the straight-line method for all fixed assets. Repairs and maintenance costs are expensed as incurred. Intangible Assets The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin ® In July 2014, the Company acquired the United States patent application for the manufacturing of Fortetropin ® Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Our policy is to evaluate intangible assets subject to amortization for possible impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. There were no impairment charges for the three months ended March 31, 2019 and the year ended December 31, 2018. Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, 2019 2018 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,047 ) (994 ) Less: accumulated amortization - website (261 ) (242 ) Total intangible assets, net $ 1,173 $ 1,245 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, amortization expense for intangible assets is estimated to be as follows: Years Ended December 31, Amount 2019 (remaining nine months) $ 214 2020 232 2021 232 2022 232 2023 210 2024 53 Total $ 1,173 Revenue Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Accounts Receivable Credit is extended based upon an evaluation of the customer’s financial condition. Accounts receivable are stated at their estimated net realizable value. Any allowance for doubtful accounts is based on an analysis of customer accounts and historical experience. Contract Liabilities Contract liabilities may include deferred revenue related to customer payments made in advance of the customer obtaining control of the product, as well as liabilities associated with sales incentives. At March 31, 2019 and December 31, 2018, the Company had no contract liability balances. Disaggregation of Revenue Our net revenues by product type are presented below for the three months ended March 31, 2019 and 2018. Three months ended Product Type March 31, March 31, Qurr® (1) $ 16 50 Yolked® (2) 68 - Myos Canine Muscle Formula® (3) 61 - Physician Muscle Health Formula (4) 4 7 Total Net Revenues $ 149 57 (1) Launched in March 2017 (2) Launched in March 2018 (3) Launched in June 2018 (4) Launched in May 2016 Advertising The Company charges advertising expenses to selling, marketing and research as incurred. Advertising expenses were $236 and $150 for the three months ended March 31, 2019 and 2018, respectively. Research and Development Research and development expenses consist primarily of operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Research and development expenses were $9 and $186 for the three months ended March 31, 2019 and 2018, respectively. Shipping and Handling The Company records expenses for shipping and handling of products to our customers as cost of sales. These expenses were $6 and $5 for the three months ended March 31, 2019 and 2018, respectively. Stock-based Compensation Stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Share-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. These expenses are included as personnel and benefits within the condensed consolidated statements of operations. Stock-based compensation expenses were $243 and $123 for the three months ended March 31, 2019 and 2018, respectively. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of the fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Segment Information Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At March 31, 2019 and December 31, 2018 the Company’s financial instruments consisted primarily of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values. Basic and Diluted Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three months ended March 31, 2019 and 2018, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2019 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,083,082, which includes warrants to purchase an aggregate of 663,356 shares of common stock and options to purchase an aggregate of 224,380 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2018 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,439,942, which includes outstanding and exercisable warrants to purchase an aggregate of 821,202 shares of common stock, and vested stock options to purchase an aggregate of 618,740 shares of common stock. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes For the three months ended March 31, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019 with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of early adoption of this ASU and determined that it will not have a significant impact on its condensed consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new guidance expands the scope of Topic 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity's own operations, and supersedes the guidance in ASC 505-50, Equity-Based Payments to Non-Employees. The most significant change resulting from this update is that stock-based awards granted to non-employees will no longer need to be re-measured at fair value at each financial reporting date until performance is complete, as these awards will be measured at fair value at the grant date. The guidance is effective January 1, 2019 with early adoption permitted, including in an interim period for which financial statements have not been issued. The Company has evaluated the impact of early adoption of this ASU and determined that it will not have a significant impact on its condensed consolidated financial statements. In March 2018, the FASB issued ASU 2018-5 – Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 118. This ASU provided guidance related to Securities and Exchange Commission ("SEC") Staff Accounting Bulletin No. 118 ("SAB 118"), which addresses the accounting implications of the Tax Act. SAB 118 allows a company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date and was effective upon issuance. We have analyzed the Tax Act, and in certain areas, have made reasonable estimates of the effects on our condensed consolidated financial statements and tax disclosures. In September 2017, the FASB issued ASU No. 2017-13, Revenue from Contracts with Customers which amended FASB Accounting Standards Codification (ASC) by creating Topic 606, Revenue from Contracts with Customers. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" ("ASU 2014-09"). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The FASB also issued the following amendments to ASU No. 2014-09 to provide clarification on the guidance: ● ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date ● ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606) – Principal versus Agent (Reporting Revenue Gross vs. Net) ● ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606) – Identifying Performance Obligations and Licensing ● ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606) – Narrow-Scope Improvements and Practical Expedients The adoption of Topic 606 is required for public entities for reporting periods beginning after December 15, 2017. The Company has adopted the provisions of this ASU for its fiscal year beginning January 1, 2018 using the modified retrospective transition method. This method involves application of the new guidance to either: (a) all contracts at the date of initial application or (b) only contracts that are not completed at the date of initial application. Under this method, if necessary, a cumulative effect adjustment is recognized as of the date of initial application. The adoption of ASU 2014-09 did not have an impact on the Company and therefore, no cumulative effect adjustment was required. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718). The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. This accounting guidance was effective for us beginning January 1, 2018. The Company has evaluated the impact of the updated guidance and has determined that the adoption of ASU 2017-09 did not have a significant impact on its condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, "Simplifying the Test for Goodwill", which eliminates the second step in the current goodwill impairment calculation. Currently there is a two-step process for determining the amount of any goodwill impairment. In Step 1 an entity determines if the carrying value of the reporting unit (for which goodwill has been recorded) exceeds the fair value of the reporting unit. If the calculation in Step 1 indicates that the carrying value of a reporting unit for which goodwill has been recorded exceeds the fair value, the entity would have to determine the implied fair value of the reporting unit's goodwill. An impairment would be recorded to the extent that the goodwill carrying value exceeded the implied fair value of goodwill at the reporting date. The amount of any goodwill impairment must take into consideration the effects of income taxes for any tax deductible goodwill. The effective date to adopt the ASU is for fiscal years beginning after December 15, 2019. The ASU is to be applied prospectively. Early adoption is permitted. The Company has evaluated the impact of the updated guidance and has determined that the adoption of ASU 2017-04 is not expected to have a significant impact on its condensed consolidated financial statements. In February 2016, the FASB issued its final standard on lease accounting, ASU No. 2016-02, "Leases (Topic 842)," which superseded Topic 840, "Leases," which was further modified in ASU No. 2018-10, "Codification Improvements to Topic 842, Leases," ASU No. 2018-11, "Leases (Topic 842) Targeted Improvements" and ASU No. 2019-01 "Leases (Topic 842) Codification Improvements" to clarify the implementation guidance. The new accounting standard was effective for the Company beginning on January 1, 2019 and required the recognition on the balance sheet of right-of-use assets and lease liabilities for all long-term leases, including operating leases, on the balance sheet. The Company elected the optional transition method and adopted the new guidance on January 1, 2019 on a modified retrospective basis with no restatement of prior period amounts. As allowed under the new accounting standard, the Company elected to apply practical expedients to carry forward the original lease determinations, lease classifications and accounting of initial direct costs for all asset classes at the time of adoption. The Company also elected not to separate lease components from non- lease components and to exclude short-term leases from its condensed consolidated balance sheet. The Company's adoption of the new standard resulted in the recognition of right-of-use assets of $236 and liabilities of $245, with no material cumulative effect adjustment to equity as of the date of adoption. In connection with the adoption of this guidance, as required, the Company reclassified deferred rent liabilities as reductions to lease assets. Adoption of the new standard did not have a material impact on the Company's condensed consolidated statements of operations or cash flows. See Note 13- LEASES for additional information.

Inventories, Net

Inventories, Net	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET Inventories, net at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, Raw materials $ 1,655 $ 1,769 Work in process 18 37 Finished goods 178 135 1,851 1,941 Less: inventory reserves (165 ) (265 ) Inventories, net $ 1,686 $ 1,676

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS Fixed assets at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation (288 ) (281 ) Net book value of fixed assets $ 142 $ 149 Depreciation expense was $7 and $11 for the three months ended March 31, 2019 and 2018, respectively.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2019
Prepaid Expenses [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 6 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses and other current assets at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, Prepaid research & development $ 37 $ - Prepaid expenses 98 - Prepaid other 18 10 Total prepaid expenses and other current assets $ 153 $ 10

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of estimated future payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses and other current liabilities at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, Professional fees $ 85 $ 85 Research & development 32 91 Board compensation - 181 Other 1 26 Total accrued expenses and other current liabilities $ 118 $ 383

Promissory Note Payable

Promissory Note Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
PROMISSORY NOTE PAYABLE	NOTE 8 - PROMISSORY NOTE PAYABLE On August 30, 2018, the Company executed an unsecured promissory note (the “Note”) in the principal amount of $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). Pursuant to the Note, on August 30, 2018, the Lender advanced $500 of funds to the Company. On September 26, 2018, the Lender advanced an additional $250 of funds to the Company. The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The proceeds of the Note will be used by the Company for general working capital purposes. On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. The Company drew down an additional $250 under the Note in December 2018. As of December 31, 2018, the balance of the Note was $1,000 and the Company accrued $15 of interest expense. In March 2019 $250 of the Note was converted into 171,233 shares as part of a private placement. As of March 31, 2019, the balance of the Note was $750 and the Company accrued $25 of interest expense.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	Note 9 – Stockholders’ Equity Preferred Stock Purchase Rights Effective February 14, 2017, the Board of Directors declared a dividend of one right (“Right”) for each of the Company’s issued and outstanding shares of common stock. The Rights were granted to the stockholders of record at the close of business on February 24, 2017. Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company’s Series A Preferred Stock at a price of $7.00, subject to certain adjustments. The Rights are not exercisable until the occurrence of certain events, including a person acquiring or obtaining the right to acquire beneficial ownership of 10% or more of the Company’s outstanding common stock. The Rights are evidenced by certificates for the common stock and automatically transfer with the common stock unless they become exercisable. If the Rights become exercisable, separate certificates evidencing the Rights will be distributed to each holder of common stock. Holders of the preferred stock will be entitled to certain dividend, liquidation and voting rights. The rights are redeemable by us at a fixed price as determined by the Board, after certain defined events. As of March 31, 2019, the Rights have no dilutive effect on the earnings per common share calculation and no shares of preferred stock have been issued. At the time of issuance, the Company determined that these Rights have a de minimis fair value. The description and terms of the Rights are set forth in the Rights Agreement dated as of February 14, 2017 between the Company and Island Stock Transfer, as Rights Agent. Issuance of Common Stock The Company has periodically issued common stock in connection with certain private and public offerings. For the three months ended March 31, 2019 and 2018 the Company has received aggregate gross proceeds of $2,312 and $296 from these offerings: Gross Date Shares Proceeds March 27, 2019 1,438,356 (1) $ 2,100 January 1, 2019 thru March 31, 2019 111,129 (2) 212 January 19, 2018 140,295 (3) 296 (1) Shares issued pursuant to a private placement with accredited investors for $1.46 per share. (2) Shares of common stock sold for between $1.85 and $2.00 per share in at-the-market offerings. (3) Shares of common stock sold for $2.111 per share in an at-the-market offering.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2019
Other Liabilities Disclosure [Abstract]
WARRANTS	Note 10 – Warrants The following table summarizes information about outstanding and exercisable warrants at March 31, 2019: Number of Shares Shares Shares Underlying Underlying Underlying Warrants Warrants Warrants Exchanged, Outstanding Expiration Originally Exercised and Exercise Term Description Grant Date Granted or Expired Exercisable Price in years Series B (1) January 27, 2014 157,846 (157,846 ) - $ - - Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 0.75 Repricing Series C (2) November 19, 2014 142,957 142,957 $ 9.00 0.75 Repricing Series E (2) November 19, 2014 - 142,957 142,957 $ 9.00 0.75 Rens (3) March 3, 2016 375,000 - 375,000 $ 7.00 0.75 Total 678,245 (14,889 ) 663,356 (1) Issued in connection with the January 27, 2014 private placement transaction and which expired in January 2019. (2) Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015. (3) Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK COMPENSATION	NOTE 11 – STOCK COMPENSATION Equity Incentive Plan In November 2016, the Company increased the number of shares available for issuance under its 2012 Equity Incentive Plan (as amended, the “Plan”) from 550,000 to 850,000, which was approved by the Company’s shareholders in December 2016. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. As of March 31, 2019, the remaining shares of common stock available for future issuances of awards was 231,260. The Company granted an aggregate of 30,000 options to purchase restricted common stock to certain directors prior to the adoption of the Plan. Stock options generally vest and become exercisable with respect to 100% of the common stock subject to such stock option on the third (3rd) anniversary of the date of grant. Any unvested portion of a stock option shall expire upon termination of employment or service of the participant granted the stock option, and the vested portion shall remain exercisable in accordance with the provisions of the Plan. Stock Options The following table summarizes stock option activity for the three months ended March 31, 2019: Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2018 598,740 $ 6.76 5.65 Options granted during the three months ended March 31, 2019 52,000 2.00 9.75 Balance at March 31, 2019 650,740 $ 4.83 8.55 At March 31, 2019 and December 31, 2018, the exercisable options had no intrinsic value. As of March 31, 2019, 451,480 options have vested and 199,260 options remain unvested. The vesting terms range from zero to 4 years and the vested options have a weighted average remaining term of 5.65 years and a weighted average exercise price of $6.76 per share. The weighted average grant date fair value of the 52,000 stock options granted during the three months ended March 31, 2019 was $0.76. The following table summarizes the assumptions used to value stock using a Black-Scholes model: Expected annualized volatility: 50.00 % Annual risk-free interest rate: 2.38 % Expected time to maturity: 7 years Exercise Price $ 2.00 The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected annualized volatility is based on the volatility of the Company’s historical stock prices. Stock-Based Compensation: Stock-based compensation consists of expenses related to the issuance of stock options and restricted stock. Stock-based compensation expenses were $243 and $123 for the three months ended March 31, 2019 and 2018, respectively.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 12 – Commitments and Contingencies Supply Agreement On November 18, 2016, the Company entered into an Amended Supply Agreement with DIL Technologie GmbH (“DIL”). Pursuant to the agreement (and so long as the agreement is effective), DIL will manufacture and supply the Company with Fortetropin®, the active ingredient for its products, and the Company will purchase quantities of Fortetropin® from DIL in its discretion. DIL will manufacture the formula exclusively for the Company in perpetuity, and may not manufacture the formula for other entities (but may manufacture it for its own non-commercial research). The Company agreed, commencing January 2017, to pay DIL €10 (approximately $12) per month for collaborative research. The monthly payments terminate upon the earlier of: (a) the date that the Company orders additional product in accordance with the terms of the agreement and (b) December 31, 2018, and the Company has no further financial obligations to DIL thereafter. The agreement expired on December 31, 2018 and the Company has not renewed it. Defined Contribution Plan The Company established a 401(k) Plan (the “401(k) Plan”) for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(k) Plan. The 401(k) Plan is a defined contribution plan that provides that participants may make salary deferral contributions up to the maximum allowed by law (subject to catch-up contributions) in the form of voluntary payroll deductions. The Company’s matching contribution is equal to 100 percent on the first four percent of a participant’s compensation which is deferred as an elective deferral. The Company’s aggregate matching contributions were $8 and $8 for the three months ended March 31, 2019 and 2018, respectively. Product Liability As a manufacturer of nutritional supplements that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any claims to date, it is possible that future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance of $5 million per-occurrence and a $10 million annual aggregate coverage. At March 31, 2019 and December 31, 2018, the Company had not recorded any accruals for product liability claims.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
LEASES	Note 13 – LEASES Operating Leases The Company has operating leases for its executive office and office equipment. The remaining terms on these leases range from 4 to 5 years. The Company entered into an operating lease in August 2012, which was amended in March 2019, for its executive office located at 45 Horsehill Road, Suite 106, Hanover Township, Morris County, New Jersey, which consists of approximately 5,225 square feet of space. The lease agreement expires in December 2022 and contains an additional three year option to extend the lease and annual escalating payments. We used a discount rate of 12% to calculate the right of use asset and operating lease liability recorded on our condensed consolidated balance sheet . The Company uses this facility as its corporate headquarters, and as its research and manufacturing facility. The Company’s office equipment operating lease is for a copier and the agreement expires in November 2023. The components of lease expense of $16 for the three months ended March 31, 2019 were recorded in the condensed consolidated statement of operations. The following table provides a breakdown of lease balances within the condensed consolidated balance sheet as of March 31, 2019: March 31, Operating lease right of use asset $ 224 Operating lease liability: Lease Liability : current $ 46 Lease Liability : non-current 185 Total operating lease liability $ 231 Other information related to leases are as follows: March 31, Cash paid for rent included in the measurement of operating lease liabilities cash flows $ 19 Right-of-use asset obtained in exchange for new operating lease liability - Weighted-average remaining lease term- operating leases, in years 3.79 Weighted-average discount rate - operating leases 11.7 % Future minimum lease payments for operating leases with initial or remaining noncancellable lease terms in excess of one year as of March 31, 2019 are as follows: For years ending Amount 2019 (remaining nine months) $ 56 2020 69 2021 77 2022 80 2023 3 Thereafter - Total future minimum lease payments $ 285 Imputed interest (54 ) Total Lease Liability $ 231 There were no material operating leases that the Company had entered into and that were yet to commence as of March 31, 2019.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Note 14 – Related Party Transactions The following is a description of the transactions we have engaged in with our directors, director nominees and officers and beneficial owners of more than five percent of our voting securities and their affiliates: On August 30, 2018, the Company executed an unsecured promissory note (the “Note”) in the principal amount of $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The Note includes standard events of default including non-payment of the principal or accrued interest due on the Note. On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. The Company drew down an additional $250 under the Note in December 2018. As of December 31, 2018, the balance of the Note was $1,000 and the Company accrued $15 of interest expense. In March 2019, $250 of the Note was converted into 171,233 shares as part of a private placement. As of March 31, 2019, the balance of the Note was $750 and the Company accrued $25 of interest expense.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2019
Legal Proceedings [Abstract]
LEGAL PROCEEDINGS	Note 15 – legal PROCEEDINGS On January 6, 2017, in connection with the financing contemplated by a securities purchase agreement with RENS Technology Inc. (the “Purchaser”), we commenced an action in the Supreme Court of New York, County of New York (the “Court”), against the Purchaser, RENS Agriculture, the parent company of the Purchaser, and Ren Ren, a principal in both entities and one of our directors, arising from the Purchaser’s breach of the agreement under which the Purchaser agreed to invest an aggregate of $20.25 million in our company in exchange for an aggregate of 3,537,037 shares of our common stock and warrants to purchase an aggregate of 884,259 shares of common stock. On April 11, 2017, the Court noted that we had demonstrated a likelihood of success on the merits of the breach of contract claim. Thereafter, a hearing was scheduled on the application by the Purchaser to dismiss the complaint and various pre-trial discovery applications by both parties. In August 2017, before the hearing occurred, the Company amended its complaint repeating most of the initial claims but adding several additional claims against RENS Agriculture, Mr. Ren and two additional Chinese defendants, including a claim against RENS Agriculture for breaching the exclusive distribution agreement, as well as claims against all defendants for theft and misappropriation of our confidential proprietary information and trade secrets, breach of fiduciary duty and duty of loyalty, misappropriation of corporate opportunity, unfair competition and a number of other torts. We are seeking damages and injunctive relief. The Purchaser has filed a motion to dismiss the amended complaint, which is still pending and scheduled for oral argument in the second quarter of 2019. The parties are currently in settlement discussions regarding the foregoing matter. The outcome of this matter cannot be determined as of the date of these condensed consolidated f inancial statements. On August 16, 2017, the Purchaser commenced an action in the District Court of Clark County in the State of Nevada against us and Joseph Mannello, our then interim Chief Executive Officer, alleging that Mr. Mannello had breached his fiduciary duties and had mismanaged our company. The action sought monetary damages against Mr. Mannello and the appointment of a receiver over our company. The Purchaser filed an application to appoint a receiver, and Mr. Mannello and our company filed a motion to dismiss the action. On April 11, 2019, the parties filed, and the court entered, a Stipulation and Order of dismissal which dismissed this action in its entirety.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed c onsolidated financial statements include the accounts of MYOS RENS Technology Inc. and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated in consolidation.
Reclassification of Prior Period Presentation	Reclassification of Prior Period Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no impact on the Company’s prior year net loss or stockholders’ equity.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statement s and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated f inancial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the amount of deferred offering costs recognized, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts. Management believes that we have the ability to sell raw materials to a third party in the event the Company does not obtain the requisite amount of revenue.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2019 and December 31, 2018 the Company had no cash equivalents. As part of our ongoing liquidity assessments, management evaluates our cash and cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The amount of funds held in these accounts can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits.
Inventory Reserves	Inventory Reserves Inventories are valued at the lower of cost or net realizable value, with cost determined on a first in, first-out basis. Each quarter the Company evaluates the need for a change in the inventory reserve based on projected future sales and expiration dates of products. Our policy is to recognize an inventory reserve as a loss in earnings in the period in which evidence exists that the net realizable value of inventory is less than its cost due to damage, physical deterioration, obsolescence, and changes in inventory reserve estimates, changes in price levels or other causes. Net realizable value is the estimated selling price in the ordinary course of business, less costs to complete and sell finished goods, including direct selling costs such as transportation and sales commissions as well as inventory write-offs. The multiple possible outcomes that can result from applying lower of cost or net realizable value can make inventory valuation highly complex. For the three months ended March 31, 2019 no additional reserve was recorded within cost of sales on the condensed consolidated statements of operations.
Deferred Offering Costs	Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations during the period in accordance with SEC guidance. Since the February 21, 2017 sales agreement expired by June 30, 2018 the remaining deferred offering costs of $96 on the Company’s condensed consolidated balance sheets were recognized and recorded within the Company’s condensed consolidated statements of operations as general and administrative expenses. On July 24, 2018, the Company entered into a new sales agreement, incurring $108 of deferred offering costs. As of March 31, 2019, $92 of deferred offering costs is included as a long term asset on the accompanying condensed consolidated balance sheet.
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating lease assets and liabilities are included in operating lease right of use (“ROU”) lease assets, current portion of operating lease liabilities, and long term operating lease liabilities on the Company’s condensed consolidated balance sheets. Operating lease right of use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right of use assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Since the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating right of use assets also include any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Fair Value of Long-Lived Assets	Fair Value of Long-Lived Assets We test long-lived assets, including fixed assets and intangibles with finite lives, for recoverability when events or changes in circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate we utilize to evaluate potential investments. We estimate fair value based on the information available in making the necessary estimates, judgments and projections.
Fixed Assets	Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset’s useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the condensed consolidated statements of operations. Depreciation is provided using the straight-line method for all fixed assets. Repairs and maintenance costs are expensed as incurred.
Intangible Assets	Intangible Assets The Company's intangible assets consist primarily of intellectual property pertaining to Fortetropin ® In July 2014, the Company acquired the United States patent application for the manufacturing of Fortetropin ® Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor's patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Our policy is to evaluate intangible assets subject to amortization for possible impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. There were no impairment charges for the three months ended March 31, 2019 and the year ended December 31, 2018. Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following: March 31, December 31, 2019 2018 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,047 ) (994 ) Less: accumulated amortization - website (261 ) (242 ) Total intangible assets, net $ 1,173 $ 1,245 Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, amortization expense for intangible assets is estimated to be as follows: Years Ended December 31, Amount 2019 (remaining nine months) $ 214 2020 232 2021 232 2022 232 2023 210 2024 53 Total $ 1,173
Revenue	Revenue Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Accounts Receivable Credit is extended based upon an evaluation of the customer's financial condition. Accounts receivable are stated at their estimated net realizable value. Any allowance for doubtful accounts is based on an analysis of customer accounts and historical experience. Contract Liabilities Contract liabilities may include deferred revenue related to customer payments made in advance of the customer obtaining control of the product, as well as liabilities associated with sales incentives. At March 31, 2019 and December 31, 2018, the Company had no contract liability balances. Disaggregation of Revenue Our net revenues by product type are presented below for the three months ended March 31, 2019 and 2018. Three months ended Product Type March 31, March 31, Qurr® (1) $ 16 50 Yolked® (2) 68 - Myos Canine Muscle Formula® (3) 61 - Physician Muscle Health Formula (4) 4 7 Total Net Revenues $ 149 57 (1) Launched in March 2017 (2) Launched in March 2018 (3) Launched in June 2018 (4) Launched in May 2016
Advertising	Advertising The Company charges advertising expenses to selling, marketing and research as incurred. Advertising expenses were $236 and $150 for the three months ended March 31, 2019 and 2018, respectively.
Research and Development	Research and Development Research and development expenses consist primarily of operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Research and development expenses were $9 and $186 for the three months ended March 31, 2019 and 2018, respectively.
Shipping and Handling Costs	Shipping and Handling The Company records expenses for shipping and handling of products to our customers as cost of sales. These expenses were $6 and $5 for the three months ended March 31, 2019 and 2018, respectively.
Stock-based Compensation	Stock-based Compensation Stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Share-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. These expenses are included as personnel and benefits within the condensed consolidated statements of operations. Stock-based compensation expenses were $243 and $123 for the three months ended March 31, 2019 and 2018, respectively. The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of the fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Segment Information	Segment Information Accounting Standards Codification ("ASC") 280, Disclosures about Segments of an Enterprise and Related Information
Fair Value Measurement	Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability's classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At March 31, 2019 and December 31, 2018 the Company's financial instruments consisted primarily of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. Due to their short-term nature, the carrying amounts of the Company's financial instruments approximated their fair values.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the "treasury stock" method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three months ended March 31, 2019 and 2018, the Company incurred a net loss. Accordingly, the Company's common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2019 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,083,082, which includes warrants to purchase an aggregate of 663,356 shares of common stock and options to purchase an aggregate of 224,380 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2018 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,439,942, which includes outstanding and exercisable warrants to purchase an aggregate of 821,202 shares of common stock, and vested stock options to purchase an aggregate of 618,740 shares of common stock.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes For the three months ended March 31, 2019 and 2018, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of intangible assets	March 31, December 31, 2019 2018 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization – intellectual property (1,047 ) (994 ) Less: accumulated amortization - website (261 ) (242 ) Total intangible assets, net $ 1,173 $ 1,245
Schedule of intangible assets is estimated useful lives	Years Ended December 31, Amount 2019 (remaining nine months) $ 214 2020 232 2021 232 2022 232 2023 210 2024 53 Total $ 1,173
Schedule of disaggregation of revenue	Three months ended Product Type March 31, March 31, Qurr® (1) $ 16 50 Yolked® (2) 68 - Myos Canine Muscle Formula® (3) 61 - Physician Muscle Health Formula (4) 4 7 Total Net Revenues $ 149 57 (1) Launched in March 2017 (2) Launched in March 2018 (3) Launched in June 2018 (4) Launched in May 2016

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventories, net	March 31, December 31, Raw materials $ 1,655 $ 1,769 Work in process 18 37 Finished goods 178 135 1,851 1,941 Less: inventory reserves (165 ) (265 ) Inventories, net $ 1,686 $ 1,676

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of fixed assets	March 31, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation (288 ) (281 ) Net book value of fixed assets $ 142 $ 149

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Prepaid Expenses [Abstract]
Schedule of prepaid expenses and other current assets	March 31, December 31, Prepaid research & development $ 37 $ - Prepaid expenses 98 - Prepaid other 18 10 Total prepaid expenses and other current assets $ 153 $ 10

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of accrued expenses and other current liabilities	March 31, December 31, Professional fees $ 85 $ 85 Research & development 32 91 Board compensation - 181 Other 1 26 Total accrued expenses and other current liabilities $ 118 $ 383

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of periodical gross proceeds from private placements	Gross Date Shares Proceeds March 27, 2019 1,438,356 (1) $ 2,100 January 1, 2019 thru March 31, 2019 111,129 (2) 212 January 19, 2018 140,295 (3) 296 (1) Shares issued pursuant to a private placement with accredited investors for $1.46 per share. (2) Shares of common stock sold for between $1.85 and $2.00 per share in at-the-market offerings. (3) Shares of common stock sold for $2.111 per share in an at-the-market offering.

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Other Liabilities Disclosure [Abstract]
Schedule of outstanding and exercisable warrants issued to private placement	Number of Shares Shares Shares Underlying Underlying Underlying Warrants Warrants Warrants Exchanged, Outstanding Expiration Originally Exercised and Exercise Term Description Grant Date Granted or Expired Exercisable Price in years Series B (1) January 27, 2014 157,846 (157,846 ) - $ - - Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 0.75 Repricing Series C (2) November 19, 2014 142,957 142,957 $ 9.00 0.75 Repricing Series E (2) November 19, 2014 - 142,957 142,957 $ 9.00 0.75 Rens (3) March 3, 2016 375,000 - 375,000 $ 7.00 0.75 Total 678,245 (14,889 ) 663,356 (1) Issued in connection with the January 27, 2014 private placement transaction and which expired in January 2019. (2) Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015. (3) Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation (Tables)

Stock Compensation (Tables) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2018 598,740 $ 6.76 5.65 Options granted during the three months ended March 31, 2019 52,000 2.00 9.75 Balance at March 31, 2019 650,740 $ 4.83 8.55
Schedule of assumptions used to value stock options granted using a Black-Scholes model	Expected annualized volatility: 50.00 % Annual risk-free interest rate: 2.38 % Expected time to maturity: 7 years Exercise Price $ 2.00

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases Tables Abstract
Schedule of breakdown of lease balances within our condensed consolidated balance sheet	March 31, Operating lease right of use asset $ 224 Operating lease liability: Lease Liability : current $ 46 Lease Liability : non-current 185 Total operating lease liability $ 231
Schedule of other information related to leases	March 31, Cash paid for rent included in the measurement of operating lease liabilities cash flows $ 19 Right-of-use asset obtained in exchange for new operating lease liability - Weighted-average remaining lease term- operating leases, in years 3.79 Weighted-average discount rate - operating leases 11.7 %
Schedule of future minimum rent payments	For years ending Amount 2019 (remaining nine months) $ 56 2020 69 2021 77 2022 80 2023 3 Thereafter - Total future minimum lease payments $ 285 Imputed interest (54 ) Total Lease Liability $ 231

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 15, 2019	Nov. 13, 2018	Dec. 17, 2015	Mar. 27, 2019	Mar. 19, 2019	Dec. 31, 2018	Aug. 30, 2018	Apr. 25, 2018	Jan. 19, 2018	Feb. 21, 2017	Dec. 17, 2015	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Feb. 15, 2019	Sep. 27, 2018	Sep. 26, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Offering costs value												$ 212	$ 290
Net loss												(975)	(1,213)
Cash						$ 15						2,197	230	$ 15
Working capital												2,905
Current assets						2,903						4,055		2,903
Current liabilities						$ 1,634						1,150		$ 1,634
Net cash used in operating activities												104	(989)
Aggregate gross proceeds							$ 176		$ 296			$ 1,850
Shares of common stock	32,489						131,225		140,295			771,520
Sale of stock price per share				$ 1.46	$ 1.85	$ 1.85						$ 2		$ 1.85	$ 2			$ 2.111
Gross proceeds from sale of stock	$ 65				$ 146							$ 1,755
Sale of Common stock, shares					78,640							882,649
Common stock, par value						$ 0.001						$ 0.001		$ 0.001
Deferred offering costs													108
Common stock offer shares												$ 1,850
Remaining deferred offering costs												96
Unsecured promissory note principal amount							$ 750
Lender advanced additional of funds							$ 500										$ 250
Note payable, description						The Company drew down an additional $250 under the Note in December 2018. As of December 31, 2018, the balance of the Note was $1,000 and the Company accrued $15 of interest expense.	The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty.
Accrued of interest expense												$ 25
Converted into shares												171,233
Deferred offering costs expenses												$ 16	$ 6
Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount drawn down		$ 750
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount drawn down		$ 1,000
Cenegenics [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales
Joseph Mannello [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unsecured promissory note principal amount							$ 750
Lender advanced additional of funds						$ 250	$ 500							$ 250		$ 250
Accrued interest percentage							5.00%
Converted into shares							250
Rens Technology Inc [Member] | Securities Purchase Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate common shares			3,537,037
Payments of financing			$ 20,500
Common stock, par value			$ 0.001								$ 0.001
Rens Technology Inc [Member] | Securities Purchase Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Purchaser acquired, shares											1,500,000
Warrants acquired											375,000
Purchaser acquired, value											$ 5,250
Securities close date, description											The first tranche, which closed on March 3, 2016.
Private Placement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gross proceeds of common stock value								$ 1,000
Shares of common stock				1,438,356				806,452
Sale of stock price per share				$ 1.46				$ 1.24
Gross proceeds from sale of stock				$ 1,850
Net proceeds from private sale of stock								$ 978
Related party note payable				$ 250
H C Wainwright [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Offering costs value										$ 6,000
Payments of financing										125
Deferred offering costs										$ 96

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Intangibles with finite lives:
Intangibles with finite lives		$ 1,245
Less: accumulated amortization
Total intangible assets, net	$ 1,173	1,245
Intellectual property [Member]
Intangibles with finite lives:
Intangibles with finite lives	380	2,101
Less: accumulated amortization	(261)	(994)
Website - qurr.com [Member]
Intangibles with finite lives:
Intangibles with finite lives	2,101	380
Less: accumulated amortization	$ (1,047)	$ (242)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
2019 (remaining nine months)	$ 214
2020	232
2021	232
2022	232
2023	210
2024	53
Total	$ 1,173	$ 1,245

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total Net Revenues		$ 149	$ 57
Qurr® [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[1]	16	50
Yolked® [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[2]	68
Myos Canine Muscle Formula [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[3]	61
Physician Muscle Health Formula [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[4]	$ 4	$ 7
[1]	Launched in March 2017
[2]	Launched in March 2018
[3]	Launched in June 2018
[4]	Launched in May 2016

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Jul. 31, 2014	Apr. 30, 2014	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Feb. 21, 2017
Summary of Significant Accounting Policies (Textual)
Deferred offering costs				$ 108
Estimated useful life of intangible assets	10 years
Intangible asset acquired	$ 101
Discount rate	10.00%
Advertising and promotional costs			$ 236	150
Research and development cost			9	186
Amortization			72	72
Share based compensation			243	$ 123
Deferred offering costs			$ 92		$ 108	$ 96
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful lives of fixed assets			P3Y
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful lives of fixed assets			P7Y
Intellectual Property [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets		10 years
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets	20 years
Employee Stock Option [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding			1,083,082	1,439,942
Sale of product			$ 6	$ 5
Warrants to purchase shares of common stock			663,356	821,202
Options to purchase shares of common stock			224,380	618,740
Share based compensation			$ 243	$ 123

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Summary of Inventory
Raw materials	$ 1,655	$ 1,769
Work in process	18	37
Finished goods	178	135
Inventories, gross	1,851	1,941
Less: inventory reserves	(165)	(265)
Inventories, net	$ 1,686	$ 1,676

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Summary of fixed assets
Total fixed assets	$ 430	$ 430
Less: accumulated depreciation	(288)	(281)
Net book value of fixed assets	142	149
Furniture, fixtures and equipment [Member]
Summary of fixed assets
Total fixed assets	116	116
Computers and software [Member]
Summary of fixed assets
Total fixed assets	68	68
Leasehold improvements [Member]
Summary of fixed assets
Total fixed assets	239	239
Other [Member]
Summary of fixed assets
Total fixed assets	$ 7	$ 7

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fixed Assets (Textual)
Depreciation expense	$ 7	$ 11

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Summary of prepaid expenses and other current assets
Prepaid research & development	$ 37
Prepaid expenses	98
Prepaid other	18	10
Total prepaid expenses and other current assets	$ 153	$ 10

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Professional fees	$ 85	$ 85
Research & development	32	91
Board compensation		181
Other	1	26
Total accrued expenses and other current liabilities	$ 118	$ 383

Promissory Note Payable (Detail

Promissory Note Payable (Details) - USD ($) $ in Thousands	Nov. 13, 2018	Dec. 31, 2018	Aug. 30, 2018	Mar. 31, 2019	Sep. 26, 2018
Promissory Note Payable (Textual)
Unsecured promissory note principal amount			$ 750
Lender advanced additional of funds			$ 500		$ 250
Note payable, description		The Company drew down an additional $250 under the Note in December 2018. As of December 31, 2018, the balance of the Note was $1,000 and the Company accrued $15 of interest expense.	The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty.
Converted into value of private placement				$ 250
Converted into shares of private placement				171,233
Balance of note				$ 750
Accrued of interest expense				25
Note Payable [Member]
Promissory Note Payable (Textual)
Converted into value of private placement				$ 250
Converted into shares of private placement				171,233
Minimum [Member]
Promissory Note Payable (Textual)
Amount drawn down under the note	$ 750
Maximum [Member]
Promissory Note Payable (Textual)
Amount drawn down under the note	$ 1,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Class of Stock [Line Items]
Gross Proceeds		$ 1,850
Common Stock [Member] | March 27, 2019 [Member]
Class of Stock [Line Items]
Shares	[1]	1,438,356
Gross Proceeds		$ 2,100
Common Stock [Member] | January 1, 2019 thru March 31, 2019 [Member]
Class of Stock [Line Items]
Shares	[2]	111,129
Gross Proceeds		$ 212
Common Stock [Member] | January 19, 2018 [Member]
Class of Stock [Line Items]
Shares	[3]	140,295
Gross Proceeds		$ 296
[1]	Shares issued pursuant to a private placement with accredited investors for $1.46 per share.
[2]	Shares of common stock sold for between $1.85 and $2.00 per share in at-the-market offerings.
[3]	Shares of common stock sold for $2.111 per share in an at-the-market offering.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 14, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 27, 2019	Mar. 19, 2019	Feb. 15, 2019	Dec. 31, 2018	Dec. 31, 2017
Stockholders' Equity (Textual)
Sale of stock price per share		$ 2		$ 1.46	$ 1.85	$ 2	$ 1.85	$ 2.111
Proceeds from issuance of private placement and public offering		$ 2,312	$ 296
Beneficial ownership, percentage		10.00%
Series A Preferred Stock [Member]
Stockholders' Equity (Textual)
Series A preferred stock purchase right, description	Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company's Series A Preferred Stock at a price of $7.00, subject to certain adjustments.

Warrants (Details)

Warrants (Details) - $ / shares		3 Months Ended
		Mar. 31, 2019	Jan. 31, 2019
Series B [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	[1]	Jan. 27, 2014
Number of Shares Underlying Warrants Originally Granted	[1]	157,846
Shares Underlying Warrants Exchanged, Exercised or Expired	[1]	(157,846)
Shares Underlying Warrants Outstanding and Exercisable	[1]
Exercise price	[1]
Expiration Term in years	[1]	0 years
Series C [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	[2]	Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]	145,399
Shares Underlying Warrants Exchanged, Exercised or Expired	[2]	(142,957)
Shares Underlying Warrants Outstanding and Exercisable	[2]	2,442
Exercise price	[2]	$ 12
Expiration Term in years	[2]	9 months
Repricing Series C [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	[2]	Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired	[2]	142,957
Shares Underlying Warrants Outstanding and Exercisable	[2]	142,957
Exercise price	[2]	$ 9
Expiration Term in years	[2]	9 months
Repricing Series E [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	[2]	Nov. 19, 2014
Number of Shares Underlying Warrants Originally Granted	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired	[2]	142,957
Shares Underlying Warrants Outstanding and Exercisable	[2]	142,957
Exercise price	[2]	$ 9
Expiration Term in years	[2]	9 months
Rens [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	[3]	Mar. 3, 2016
Number of Shares Underlying Warrants Originally Granted	[3]	375,000
Shares Underlying Warrants Exchanged, Exercised or Expired	[3]
Shares Underlying Warrants Outstanding and Exercisable	[3]	375,000
Exercise price	[3]	$ 7
Expiration Term in years	[3]	9 months
Warrant [Member]
Summarizes information about warrants outstanding and exercisable
Number of Shares Underlying Warrants Originally Granted		678,245
Shares Underlying Warrants Exchanged, Exercised or Expired		(14,889)
Shares Underlying Warrants Outstanding and Exercisable			663,356
[1]	Issued in connection with the January 27, 2014 private placement transaction and which expired in January 2019.
[2]	Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015.
[3]	Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation (Details)

Stock Compensation (Details) - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Under Options | shares	598,740
Options granted, Shares Under Options | shares	52,000
Ending Balance, Shares Under Options | shares	650,740
Beginning Balance, Weighted Average Exercise Price | $ / shares	$ 6.76
Options granted, Weighted Average Exercise Price | $ / shares	2
Ending Balance, Weighted Average Exercise Price | $ / shares	$ 4.83
Beginning Balance, Weighted Average Remaining Contractual Term (Years)	5 years 7 months 24 days
Options granted, Weighted Average Remaining Contractual Term (Years)	9 years 9 months
Ending Balance, Weighted Average Remaining Contractual Term (Years)	8 years 6 months 18 days

Stock Compensation (Details 1)

Stock Compensation (Details 1)	3 Months Ended
	Mar. 31, 2019$ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected annualized volatility:	50.00%
Annual risk-free interest rate:	2.38%
Expected time to maturity:	7 years
Exercise Price	$ 2

Stock Compensation (Details Tex

Stock Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Nov. 30, 2016
Stock Compensation (Textual)
Stock-based compensation expenses	$ 243	$ 123
2012 Equity Incentive Plan [Member]
Stock Compensation (Textual)
Common stock reserved for issuance	231,260
Number of option granted	30,000
Stock options exercisable, description	Stock options generally vest and become exercisable with respect to 100% of the common stock.
Number of shares vested	451,480
Number of options unvested	199,260
Vested options, weighted average remaining contractual life	5 years 7 months 24 days
Vested options weighted average exercise price, per share	$ 6.76
2012 Equity Incentive Plan [Member] | Minimum [Member]
Stock Compensation (Textual)
Number of shares authorized for issuance			550,000
Vesting terms range	0 years
2012 Equity Incentive Plan [Member] | Maximum [Member]
Stock Compensation (Textual)
Number of shares authorized for issuance			850,000
Vesting terms range	4 years
Employee Stock Option [Member]
Stock Compensation (Textual)
Number of option granted	52,000
Weighted average grant date fair value of stock options granted per shares	$ 0.76

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Nov. 18, 2016	Jan. 31, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Commitments and Contingencies (Textual)
Collaborative research, description		The Company agreed, commencing January 2017, to pay DIL €€10 (approximately $12) per month for collaborative research.
Aggregate matching contributions			$ 8	$ 8
Product liability insurance			$ 5,000		$ 10,000
Supply Agreement [Member]
Commitments and Contingencies (Textual)
Expiration date of agreement	Dec. 31, 2018

Related Party Promissory Note a

Related Party Promissory Note and Accrued Interest (Details) - USD ($) $ in Thousands	Nov. 13, 2018	Aug. 30, 2018	Mar. 31, 2019	Dec. 31, 2018	Sep. 27, 2018	Sep. 26, 2018
Related Party Promissory Note and Accrued Interest (Textual)
Lender advanced additional of funds		$ 500				$ 250
Unsecured promissory note principal amount		750
Converted into value of private placement			$ 250
Converted into shares of private placement			171,233
Balance of note			$ 750
Accrued of interest expense			$ 25
Minimum [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Amended and restated the Note to increase the maximum amount that may be drawn down under the Note	$ 750
Maximum [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Amended and restated the Note to increase the maximum amount that may be drawn down under the Note	$ 1,000
Joseph Mannello [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Lender advanced additional of funds		500		$ 250	$ 250
Unsecured promissory note principal amount		$ 750
Accrues interest percentage		5.00%
Converted into shares of private placement		250

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Leases Details Abstract
Operating lease right of use asset	$ 224
Operating lease liability
Lease Liability : current	46
Lease Liability : non-current	185
Total operating lease liability	$ 231

Leases (Details 1)

Leases (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Leases Details 1Abstract
Cash paid for rent included in the measurement of operating lease liabilities cash flows	$ 19
Right-of-use asset obtained in exchange for new operating lease liability	$ 224
Weighted-average remaining lease term- operating leases, in years	3 years 9 months 14 days
Weighted-average discount rate - operating leases	11.70%

Leases (Details 2)

Leases (Details 2) $ in Thousands	Mar. 31, 2019USD ($)
Leases Details 2Abstract
2019 (remaining nine months)	$ 56
2020	69
2021	77
2022	80
2023	3
Thereafter
Total future minimum lease payments	285
Imputed interest	(54)
Total Lease Liability	$ 231

Leases (Details Textual)

Leases (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)ft²	Mar. 31, 2018
Leases [Textual]
Lease agreement expires date		Nov. 30, 2023
Lease expense | $	$ 16
Discount rate of operating lease liability	12.00%
Minimum [Member]
Leases [Textual]
Operating leases term	4 years
Maximum [Member]
Leases [Textual]
Operating leases term	5 years
Leases agreement [Member] | Office Equipment [Member]
Leases [Textual]
Lease agreement expires date	Dec. 31, 2022
Area | ft²	5,225

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	Nov. 13, 2018	Dec. 31, 2018	Aug. 30, 2018	Mar. 31, 2019
Related Party Transactions (Textual)
Converted into private placement				$ 250
Common stock converted				171,233
Principal amount				$ 750
Maturity date			Aug. 31, 2019
Accrued interest				$ 25
Unsecured promissory note principal amount			$ 750
Description of amended and restated	The Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. The Company drew down an additional $250 under the Note.	The Company drew down an additional $250 under the Note in December 2018. As of December 31, 2018, the balance of the Note was $1,000 and the Company accrued $15 of interest expense.
Joseph Mannello [Member]
Related Party Transactions (Textual)
Interest rate			5.00%
Common stock converted			250
Unsecured promissory note principal amount			$ 750

Legal Proceedings (Details)

Legal Proceedings (Details) - Rens Technology Inc [Member] $ in Thousands	Jan. 06, 2017USD ($)shares
Legal Proceedings (Textual)
Aggregate purchase of warrant	884,259
Aggregate purchase of investment | $	$ 20,250
Aggregate exchange for common stock	3,537,037